<DOC>
	<DOCNO>NCT01459913</DOCNO>
	<brief_summary>The purpose study evaluate 12-week total regimen telaprevir combination pegylated interferon alfa 2a ( Peg-IFN-alfa-2a ) ribavirin ( RBV ) ( T12/PR12 ) safe effective subject interleukin-28B ( IL28B ) CC genotype . The subject enrol study chronic hepatitis C virus ( HCV ) infection cirrhosis liver .</brief_summary>
	<brief_title>Efficacy 12-Week Regimen Telaprevir , Pegylated Interferon , Ribavirin Treatment-Naive Prior Relapser Subjects With Interleukin28B ( IL28B ) CC Genotype</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female subject , 18 70 year age , inclusive Treatmentnaive OR subject ( prior relapsers ) may include achieve sustain viral response 24 week last plan dose study drug ( SVR24 ) least 1 prior course PegIFN/RBV therapy standard duration document undetectable HCV RNA level plan end treatment least 42week duration Subjects IL28B CC genotype determine screening Subjects genotype 1 chronic hepatitis C laboratory evidence HCV infection least 6 month , define ( 1 ) document HCV serology test least 6 month first screen visit demonstrate presence antiHCV antibody , ( 2 ) document presence HCV RNA sensitive specific assay least 6 month first screen visit , ( 3 ) document histologic evidence chronic hepatitis C demonstrate fibrosis standardize histologic grade system least 6 month first screen visit . If inflammation present liver histologic report , 6 month laboratory evidence require Subjects receive previous treatment telaprevir protease inhibitor ( ) chronic hepatitis C Subjects achieve SVR24 least 1 prior course PegIFN/RBV therapy standard duration never achieve undetectable HCV RNA treatment Subjects evidence hepatic decompensation Subjects evidence cirrhosis Subjects diagnose suspected hepatocellular carcinoma Subjects cause significant liver disease addition hepatitis C , may include limited malignancy hepatic involvement , hepatitis B , drug alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , primary biliary cirrhosis . Steatosis allow clinically asymptomatic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>VX-950</keyword>
	<keyword>INCIVEK</keyword>
	<keyword>INCIVO</keyword>
</DOC>